AACR Annual Meeting | Conference

Dr. Lipkin on Cancer Prevention Vaccine in Preclinical Model of Lynch Syndrome

April 2nd 2019

Steven M. Lipkin, MD, PhD, the Gladys and Roland Harriman Professor of Medicine, professor of medicine in the Division of Gastroenterology and Hepatology, and vice chair for research in the Weill Department of Medicine at Weill Cornell Medicine; and a geneticist at NewYork-Presbyterian/Weill Cornell Medical Center, discusses a study of a cancer prevention vaccine in a preclinical model of Lynch syndrome during the 2019 AACR Annual Meeting

Gilteritinib Improves OS in Relapsed/Refractory FLT3+ AML

April 1st 2019

Gilteritinib was found to significantly improve overall survival in patients with relapsed/refractory FLT3 mutation–positive acute myeloid leukemia, according to updated findings of the phase III ADMIRAL trial.

Umbralisib Achieves Impressive ORR in Relapsed/Refractory MZL

April 1st 2019

The PI3K-delta inhibitor umbralisib was found to demonstrate an overall response rate of 52% and show an encouraging tolerability profile in patients with relapsed/refractory marginal zone lymphoma, according to findings from a cohort of the phase IIb UNITY-NHL trial.

T-VEC Plus Chemo Hits High pCR Rate in TNBC

April 1st 2019

A majority of patients with large triple-negative breast tumors achieved pathologic complete response when treated with the viral oncolytic talimogene laherparepvec plus neoadjuvant chemotherapy.

Dr. Roychowdhury on FGFR Inhibitor Infigratinib in Cholangiocarcinoma

April 1st 2019

Sameek Roychowdhury, MD, PhD, associate professor of medical oncology, the Ohio State University Comprehensive Cancer Center, discusses a phase II study with infigratinib (BGJ398) in patients with cholangiocarcinoma.

Dr. Adusumilli on Autologous Mesothelin-Targeted CAR T Cells in Advanced Solid Tumors

April 1st 2019

Prasad S. Adusumilli, MD, surgeon, deputy chief of Thoracic Service, co-director of the Mesothelioma Program, head of Solid Tumors Cell Therapy, Cellular Therapeutics Center, at Memorial Sloan Kettering Cancer Center, discussed the results of a phase I study exploring mesothelin-targeted CAR T-cell therapy in patients with advanced solid tumors during the 2019 AACR Annual Meeting.

Osimertinib/Savolitinib Pairing Is Active in Relapsed EGFR-Mutant, MET-Amplified NSCLC

April 1st 2019

The combination of osimertinib and the MET inhibitor savolitinib demonstrated encouraging clinical activity and an acceptable risk-benefit profile in patients with EGFR-mutant, MET-amplified non–small cell lung cancer who previously received EGFR TKIs.

Nivolumab/Ipilimumab Active in High-Grade Neuroendocrine Tumors

April 1st 2019

The immune checkpoint inhibitor combination of nivolumab and ipilimumab induced a greater than 40% response rate and was well tolerated in patients with high-grade neuroendocrine carcinoma.

CAR T Cells Targeting Mesothelin Show Strong Early Signal in Advanced Solid Cancers

April 1st 2019

CAR T cells targeting mesothelin-expressing tumors demonstrated safety and efficacy in a preliminary clinical evaluation in patients with malignant pleural disease.

CAR T-Cell Therapy and Lymphodepletion Shows Early Efficacy, Tolerability in Advanced Sarcoma

April 1st 2019

The administration of HER2-directed CAR T-cell therapy and lymphodepletion chemotherapy demonstrated antitumor activity and was found to be safe in pediatric and adult patients with advanced HER2-positive sarcoma.

Pre-existing Cardiovascular Disease Linked to Higher Mortality With Abiraterone

February 28th 2019

Pre-existing cardiovascular disease was associated with an increased mortality risk during the first 6 months of abiraterone acetate treatment in patients with advanced prostate cancer.

Younger Patients With CRC Misdiagnosed, Diagnosed at Later Stages

February 28th 2019

Many younger patients see more than one doctor and face misdiagnoses before being given a diagnosis of colorectal cancer.

Study Validates Speed, Accuracy of Liquid Biopsies Identifying NSCLC Biomarkers

February 28th 2019

A liquid biopsy test detected all of the guideline-recommended biomarkers in newly diagnosed patients with metastatic non–small cell lung cancer at a similar rate but faster turnaround time to that of tissue genotyping.

Diet May Impact Response to Immunotherapy in Patients With Melanoma

February 28th 2019

Select patients with melanoma who consume a diet rich in fiber could see an improved response to treatment with immunotherapy.

Dr. Ferris on the Updated Data from CheckMate-141 in Head and Neck Cancer

April 19th 2018

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the updated findings from the CheckMate-141 trial in head and neck cancer.

Dr. Jhaveri on Results of Taselisib in PIK3CA-Mutated Metastatic Solid Tumors

April 19th 2018

Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a basket study of taselisib in patients with PIK3CA-mutated solid tumors.

Anti-PD-1 Biomarker Analysis Shows Promise for MDSCs, IFN-Gamma

April 18th 2018

A search for molecular guidance in the use of anti-PD-1 therapy in urothelial cancer pointed toward myeloid-derived suppressor cells as a potentially useful biomarker.

Mutation Burden May Help Guide First-Line Immunotherapy in NSCLC

April 18th 2018

Tumor mutational burden in non–small cell lung cancer identified patients who were more likely to respond to first-line combination immunotherapy with nivolumab and ipilimumab, an updated analysis of CheckMate-586 clinical trial data showed.

Dr. Shaw Discusses Efficacy of Lorlatinib in ALK+ NSCLC

April 18th 2018

Alice T. Shaw, MD, PhD, associate professor of medicine, Harvard Medical School, attending physician, Thoracic Cancer Program, Massachusetts General Hospital, discusses the efficacy of lorlatinib in ALK-positive non–small cell lung cancer.

Dr. Eggermont on the Impact of Adjuvant Anti-PD-L1 Agents in Melanoma

April 18th 2018

Alexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, discusses the impact of adjuvant anti–PD-L1 agents on the treatment landscape of melanoma.